Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 48-year-old woman with a history of limited cutaneous systemic sclerosis presents to the clinic with worsening episodes of painful blanching and cyanosis in her fingers upon cold exposure. She states that these episodes are becoming more frequent and severe despite wearing insulated gloves and strictly avoiding cold temperatures. Her physical examination is notable for sclerodactyly and multiple telangiectasias on her face and hands. No digital ulcers are currently present, but capillary refill is delayed during an episode in the clinic. Arrange the following therapeutic interventions in the correct order of escalation for the management of this patient's Raynaud phenomenon, starting from the most appropriate initial pharmacologic treatment to the therapy of last resort for critical digital ischemia.

  1. 1Initiate an oral dihydropyridine calcium channel blocker (e.g., nifedipine)
  2. 2Add an oral phosphodiesterase-5 inhibitor (e.g., sildenafil)
  3. 3Administer an intravenous prostanoid (e.g., epoprostenol)
  4. 4Perform a surgical digital sympathectomy

Answer

The correct escalation sequence is: 1) oral calcium channel blockers, 2) oral phosphodiesterase-5 inhibitors, 3) intravenous prostanoids, 4) surgical digital sympathectomy.
The standard of care for severe secondary Raynaud phenomenon follows a stepwise escalation: lifestyle modifications are followed by oral calcium channel blockers as first-line pharmacotherapy. If symptoms persist, a phosphodiesterase-5 inhibitor is added. For severe refractory disease with critical ischemia or digital ulcers, intravenous prostanoids are administered. Surgical digital sympathectomy is strictly a treatment of last resort for imminent tissue loss.

Step-by-Step Solution

1
Identify the underlying condition and the failure of initial conservative management.
The patient has secondary Raynaud phenomenon due to systemic sclerosis and has already failed lifestyle modifications (cold avoidance).
Confirming the failure of conservative measures justifies the initiation of pharmacologic therapy.
2
Determine the first-line pharmacologic agent for secondary Raynaud phenomenon.
Oral dihydropyridine calcium channel blockers (e.g., nifedipine, amlodipine) are selected as the initial medical intervention.
These agents promote vasodilation and are the most effective initial oral medications for reducing the frequency of attacks.
3
Identify the next step if first-line monotherapy is insufficient.
An oral phosphodiesterase-5 inhibitor (e.g., sildenafil) is added as second-line therapy.
PDE-5 inhibitors provide additional vasodilation through the nitric oxide pathway for patients with refractory symptoms.
4
Determine the intervention for severe, treatment-resistant disease or critical ischemia.
Intravenous prostanoids (e.g., epoprostenol) are utilized for severe ischemia or active digital ulceration.
IV prostanoids are potent vasodilators but require intravenous access and close monitoring, limiting their use to severe cases.
5
Identify the definitive treatment of last resort.
Surgical digital sympathectomy is placed at the end of the algorithm.
This is an invasive surgical procedure considered only for limb-threatening ischemia when maximal medical therapy has completely failed.

Key Concept

Stepwise escalation of therapy in secondary Raynaud phenomenon
Estimated Time:1m 30s
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic